The many known health risks currently associated with space travel include increased risk of cardiovascular disease, cancer, central nervous system related diseases, muscle degeneration, and changes with host-gut microbiome interactions that can have profound impact with these and other health risks. The majority of the risk from space travel stem of the two components of the space environment which are microgravity and radiation. From our earlier work (Beheshti et al, PLOS One, 2018), we predicted that there is a systemic component of the host that causes general increased health risks due to spaceflight driven by a circulating microRNA (miRNA) signature consisting of 13 miRNAs that directly regulates both p53 and TGF1. MiRNAs are small non-coding RNA molecules with a negative and post-transcriptional regulation on gene expression) are increasingly recognized as major systemic regulators of responses to stressors, including microgravity, oxidative stress, and DNA damage. In addition, due to the size and stability of miRNAs, it is known that miRNAs can circulate throughout the body and have been found in the majority of the bodily fluids including blood, urine, saliva, and tears. Here, we start to dissect the actual impact of this miRNA signature on both the radiation and microgravity components and prove that this miRNA signature actually exists in the circulation of a host. To achieve this, we obtained multiple tissues including, serum, liver, and spleen and utilizing droplet digital PCR (ddPCR), we start to show how this circulating miRNA signature impacts which component of the spaceflight. The tissue was obtained from experiments performed on C57BL/6 male mice (N=10 for each condition) that were hindlimb unloaded (HU) to simulated microgravity, irradiated with 2Gy gamma (IR), HU plus IR, and control mice under normal conditions. It was shown that these miRNAs were present in the serum as predicted by the in silico prediction from our earlier predictions. The HU vs Controls show significant increases of the predicted miRNAs in the serum for more than half of the miRNA signature, with remaining miRNAs increasing comparing to the controls close to statistical significance. IR vs control mice showed increases for the miRNAs, but not has pronounced as the HU conditions. Finally, the combination of the HU+IR vs controls showed increases for the majority of the miRNA signature. The data indicates that the miRNA signature originally predicted through in silico methods is mainly associated with the microgravity component and is circulating throughout the host resulting in a systemic impact of the miRNAs on the host. These miRNAs are shown in the literature to potentially increase health risks associated with several diseases. In addition, we have begun testing the potential of utilizing antagonists to this miRNA signature to act as a potential countermeasure to mitigate radiation impact on the organism. This work demonstrates for the first time the potential of a minimally invasive novel biomarker and countermeasure that can be used to mitigate both radiation and microgravity effects.